EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort

Rahul S Dalal iD, Puza P Sharma, Kanwal Bains, Jordan C Pruce, Jessica R Allegretti iD

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Rahul S Dalal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Piperidines, Pyrimidines, Colitis, Ulcerative. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tofacitinib is an oral JAK inhibitor for the treatment of ulcerative colitis (UC). We assessed outcomes through 78 weeks of tofacitinib therapy for UC in a real-world setting.

Methods

This retrospective cohort study included adults initiating tofacitinib for UC from May 1, 2018, to April 1, 2021, at a large academic center in the United States. The primary outcome was steroid-free clinical remission at 78 (+/-4) weeks (SFCR 78; simple clinical colitis activity index ≤2 with no corticosteroid use within 30 days). The secondary outcome was tofacitinib discontinuation due to nonresponse (treatment persistence). Additional outcomes were endoscopic response/remission and adverse events (AEs).

Results

Seventy-three patients initiated tofacitinib, with a median follow-up of 88 weeks. Among patients with available data, 31 of 60 (51.7%) achieved SFCR 78, 21 of 47 (44.7%) achieved endoscopic remission during follow-up, and 25 of 73 (34.2%) discontinued tofacitinib during follow-up due to nonresponse (including 11 patients who required colectomy). Nineteen AEs were reported among 15 patients during follow-up: shingles (n = 4, all without documented vaccinations), deep venous thrombosis (n = 2), elevated liver enzymes (n = 2), skin abscess (n = 2), pneumonia (n = 2), possible miscarriage (n = 2), norovirus (n = 1), COVID-19 (n = 1), lymphopenia (n = 1), Clostridioides difficile infection (n = 1), and heart block (n = 1). One patient discontinued therapy due to an AE (elevated liver enzymes), and no deaths occurred.

Conclusion

Tofacitinib treatment was effective in achieving SFCR for the majority of patients with UC through 78 weeks. Adverse events were consistent with the known safety profile of tofacitinib, and AEs requiring discontinuation were rare. Due to limitations regarding sample size, larger studies are needed to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesPyrimidinesColitis, UlcerativeHumansFemaleMaleRetrospective StudiesAdultMiddle AgedUnited StatesTreatment OutcomeRemission InductionProtein Kinase InhibitorsFollow-Up StudiesJanus Kinase InhibitorsColonoscopy

Stichwörter der Autor:innen

biologiceffectivenessendoscopicinflammatory bowel diseasesafetysmall molecule

Substanzen

tofacitinibPiperidinesPyrimidinesProtein Kinase InhibitorsJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Pfizer Inc, New York, NY, USA.
  • Department of Nutrition, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Rahul S Dalal, Jessica R Allegretti

Förderung

  • Pfizer

Zitieren

APA

Dalal, R. S., Sharma, P. P., Bains, K., Pruce, J. C., & Allegretti, J. R. (2024). Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad242

Vancouver

Dalal RS, Sharma PP, Bains K, Pruce JC, Allegretti JR. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad242

BibTeX
@article{Dalal2024,
  author = {Dalal, Rahul S and Sharma, Puza P and Bains, Kanwal and Pruce, Jordan C and Allegretti, Jessica R},
  title = {Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad242}
}
Kostenlos starten →